title: Finishing off fibrils.
abstract: Bortezomib shows high activity in light chain amyloidosis. Responses occur rapidly and are seen in cardiac, renal, and hepatic disease. Toxicity in this fragile population is significant.
authors.affiliation: Mayo Clinic, USA.
authors.forename: Morie
authors.initials: M
authors.lastname: Gertz